SG
CPXX

Societe Generale’s CELATOR PHARMACEUTICALS INC. COMMON STOCK CPXX Stock Holding History

Societe Generale’s Portfolio CPXX Stock Details CPXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$13.2M Buy
+436,207
New +$8.85M 0.09% 167

Other funds holding CPXX

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Societe Generale's CPXX Position: Q2 2016 in Review

Societe Generale opened a new position in CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) in Q2 2016: 436,207 shares worth $13.2M. The stake represents 0.09% of the portfolio and ranks #167 among its holdings.

119 funds tracked by Wall St. Rank hold CPXX as of Q2 2016.

  • Societe Generale held 436,207 shares of CELATOR PHARMACEUTICALS INC. COMMON STOCK worth $13.2M as of Q2 2016.
  • CELATOR PHARMACEUTICALS INC. COMMON STOCK was a new Societe Generale position in Q2 2016.
  • CELATOR PHARMACEUTICALS INC. COMMON STOCK made up 0.09% of Societe Generale's portfolio in Q2 2016, its #167 holding.
  • 119 funds tracked by Wall St. Rank held CELATOR PHARMACEUTICALS INC. COMMON STOCK as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.